Restenosis risk factor and the primary patency rate of arteriovenous fistula after initial percutaneous transluminal angioplasty: a retrospective cohort study
Main Article Content
Keywords
angioplasty, restenosis, platelet, Primary Patency
Abstract
Background: Arteriovenous fistula (AVF) is the optimal vascular access for patients because of its prolonged patency and limited problems. Nevertheless, maintenance is sometimes obstructed by stenosis. This study aimed to determine the factors associated with restenosis and primary patency rate in 12 months after Percutaneous Transluminal Angioplasty (PTA).
Method: A retrospective study of patients who underwent initial PTA between January 2018 and October 2023. The clinical variables, laboratory indicators, and surgical data were observed in this study. The restenosis factors were analyzed by univariate analysis, Cox - Regression test, and Hosmer-Lemeshow test. The Receiver Operating Characteristic (ROC) Analysis identified the cut-off Platelet Count (PC). The primary patency of AVF with restenosis risk was evaluated using the Kaplan-Meier analysis and log-rank test.
Result: A total of 54 patients were included. The Cox proportional hazard model revealed PC (p=0.004) was a risk factor for AVF restenosis. The Hosmer-Lemeshow test (χ2 = 11.130, p = 0.194) indicates our logistic regression model fits the data. Analysis of ROC identified a cut-off value of PC ≥ 210.5 x 109/L (sensitivity 85.7 %, specificity 46.2%). Primary patency rates of AVF with PC ≥ 210.5 x 109/L at 6 and 12 months (64.1% and 35.8%) were lower than those with PC< 210.5 x 10 9 /L (80.0%, 66.6%).
Conclusion: Balloon type (Drug Coated Balloon and Plain Balloon), predilating balloon, balloon diameter, and inflammatory markers showed no association with restenosis in 12 months after PTA. Platelet Count is statistically significant associated with AVF restenosis, which can predict the primary patency of AVF after initial PTA. It assists physicians in establishing the follow-up schedule and appropriate intervention to prevent HD vascular access failure within 12 months post-PTA.
References
2. Torreggiani M, Piccoli GB, Moio MR, Conte F, Magagnoli L, Ciceri P, et al. Choice of the Dialysis Modality: Practical Considerations. J Clin Med. 2023;12(9):3328. Available from: https://pubmed.ncbi.nlm.nih.gov/37176768
3. Bello AK, Okpechi IG, Levin A, Johnson DW. Variations in kidney care management and access: regional assessments of the 2023 International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA). Kidney Int Suppl. 2024/04/08. 2024;13(1):1–5. Available from: https://pubmed.ncbi.nlm.nih.gov/38619132
4. Lok CE, Huber TS, Lee T, Shenoy S, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. American Journal of Kidney Diseases. 2020;75(4 suppl 2):S1–S164. Available from: https://doi.org/10.1053/j.ajkd.2019.12.001
5. Barcena AJR, Perez JVD, Liu O, Mu A, Heralde 3rd FM, Huang SY, et al. Localized Perivascular Therapeutic Approaches to Inhibit Venous Neointimal Hyperplasia in Arteriovenous Fistula Access for Hemodialysis Use. Biomolecules. 2022;12(10):1367. Available from: https://pubmed.ncbi.nlm.nih.gov/36291576
6. Voorzaat BM, Janmaat CJ, van der Bogt KEA, Dekker FW, Rotmans JI. Patency Outcomes of Arteriovenous Fistulas and Grafts for Hemodialysis Access: A Trade-Off between Nonmaturation and Long-Term Complications. Kidney360. 2020;1(9):916–24. Available from: https://pubmed.ncbi.nlm.nih.gov/35369548
7. Khan T, Bhat M, Shah OA, Choh NA, Maqsood S, Shera TA. Percutaneous Transluminal Angioplasty of Dysfunctional Hemodialysis Vascular Access: Can Careful Selection of Patients Improve the Outcomes? Indian J Nephrol. 2022/03/16. 2022;32(3):233–9. Available from: https://pubmed.ncbi.nlm.nih.gov/35814313
8. Zhang F, Li J, Yu J, Jiang Y, Xiao H, Yang Y, et al. Risk factors for arteriovenous fistula dysfunction in hemodialysis patients: a retrospective study. Sci Rep. 2023;13(1):21325. Available from: https://pubmed.ncbi.nlm.nih.gov/38044365
9. Luo Q, Liu H, Yang Q. Analysis of Factors Influencing Restenosis after Percutaneous Transluminal Angioplasty. Blood Purif. 2022;51(12):1031–8. Available from: http://dx.doi.org/10.1159/000524159
10. Abdul Salim S, Tran H, Thongprayoon C, Fülöp T, Cheungpasitporn W. Comparison of drug-coated balloon angioplasty versus conventional angioplasty for arteriovenous fistula stenosis: Systematic review and meta-analysis. J Vasc Access. 2019;21(3):357–65. Available from: http://dx.doi.org/10.1177/1129729819878612
11. Han A, Park T, Kim HJ, Min S, Ha J, Min S-K. Editor’s Choice – Paclitaxel Coated Balloon Angioplasty vs. Plain Balloon Angioplasty for Haemodialysis Arteriovenous Access Stenosis: A Systematic Review and a Time to Event Meta-Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2021;62(4):597–609. Available from: http://dx.doi.org/10.1016/j.ejvs.2021.05.043
12. Zhu F, Yao Y, Ci H, Shawuti A. Predictive value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for primary patency of percutaneous transluminal angioplasty in hemodialysis arteriovenous fistula stenosis. Vascular. 2021;30(5):920–7. Available from: http://dx.doi.org/10.1177/17085381211039672
13. Huang C, Yao G, Hu R, Yang Y, Huang J, Ou F, et al. Outcome and Risk Factors of Restenosis Post Percutaneous Transluminal Angioplasty at Juxta-Anastomotic of Wrist Autogenous Radial-Cephalic Arteriovenous Fistulas: A Retrospective Cohort Study. Ann Vasc Surg. 2023;93:234–42. Available from: http://dx.doi.org/10.1016/j.avsg.2023.01.014
14. Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, et al. Editor’s Choice – Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(6):757–818. Available from: http://dx.doi.org/10.1016/j.ejvs.2018.02.001
15. Abbadie F, Kosmadakis G, Aguilera D, Piraud A. Duplex ultrasound-guided angioplasty of hemodialysis vascular access. J Vasc Surg. 2023;78(5):1292-1301.e3. Available from: http://dx.doi.org/10.1016/j.jvs.2023.07.007
16. Wu C-K, Tarng D-C, Yang C-Y, Leu J-G, Lin C-H. Factors affecting arteriovenous access patency after percutaneous transluminal angioplasty in chronic haemodialysis patients under vascular access monitoring and surveillance: a single-centre observational study. BMJ Open. 2022;12(1):e055763–e055763. Available from: https://pubmed.ncbi.nlm.nih.gov/35074822
17. Park JH, Yoon J, Park I, Sim Y, Kim SJ, Won JY, et al. A deep learning algorithm to quantify AVF stenosis and predict 6-month primary patency: a pilot study. Clin Kidney J. 2022;16(3):560–70. Available from: https://pubmed.ncbi.nlm.nih.gov/36865006
18. Zhang Y, Yuan F-L, Hu X-Y, Wang Q-B, Zou Z-W, Li Z-G. Comparison of drug-coated balloon angioplasty versus common balloon angioplasty for arteriovenous fistula stenosis: A systematic review and meta-analysis. Clin Cardiol. 2023/07/07. 2023;46(8):877–85. Available from: https://pubmed.ncbi.nlm.nih.gov/37417371
19. Attiq A, Afzal S, Ahmad W, Kandeel M. Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur J Pharmacol. 2024;966:176338. Available from: http://dx.doi.org/10.1016/j.ejphar.2024.176338
20. Xin Y, Zhang Z, Lv S, Xu S, Liu A, Li H, et al. Elucidating VSMC phenotypic transition mechanisms to bridge insights into cardiovascular disease implications. Front Cardiovasc Med. 2024;11:1400780. Available from: https://pubmed.ncbi.nlm.nih.gov/38803664
21. Li Y, Hu K, Li Y, Lu C, Guo Y, Wang W. The rodent models of arteriovenous fistula. Front Cardiovasc Med. 2024;11:1293568. Available from: https://pubmed.ncbi.nlm.nih.gov/38304139
22. Long J, Chen H, Huang Q, Chen X, Ellis RJ, Zanoli L, et al. Analysis of risk factors for late arteriovenous fistula failure and patency rates after angioplasty in hemodialysis patients: a retrospective cohort study. Transl Androl Urol. 2024/02/26. 2024;13(2):209–17. Available from: https://pubmed.ncbi.nlm.nih.gov/38481870
23. Yan R, Song A, Zhang C. The Pathological Mechanisms and Therapeutic Molecular Targets in Arteriovenous Fistula Dysfunction. Int J Mol Sci. 2024;25(17):9519. Available from: https://pubmed.ncbi.nlm.nih.gov/39273465
24. Yang L, Guo J, Chen M, Wang Y, Li J, Zhang J. Pan-Immune-Inflammatory Value is Superior to Other Inflammatory Indicators in Predicting Inpatient Major Adverse Cardiovascular Events and Severe Coronary Artery Stenosis after Percutaneous Coronary Intervention in STEMI Patients. Rev Cardiovasc Med. 2024;25(8):294. Available from: https://pubmed.ncbi.nlm.nih.gov/39228482
25. Shumilah AM, Othman AM, Al-Madhagi AK. Accuracy of neutrophil to lymphocyte and monocyte to lymphocyte ratios as new inflammatory markers in acute coronary syndrome. BMC Cardiovasc Disord. 2021;21(1):422. Available from: https://pubmed.ncbi.nlm.nih.gov/34493205
26. Tekin YK, Tekin G. Mean Platelet Volume-to-Platelet Count Ratio, Mean Platelet Volume-to-Lymphocyte Ratio, and Red Blood Cell Distribution Width-Platelet Count Ratio as Markers of Inflammation in Patients with Ascending Thoracic Aortic Aneurysm. Brazilian J Cardiovasc Surg. 2020;35(2):175–80. Available from: https://pubmed.ncbi.nlm.nih.gov/32369297
27. Işık F, Soner S. Platelet-to-Hemoglobin Ratio Is an Important Predictor of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Cureus. 2022;14(7):e26833–e26833. Available from: https://pubmed.ncbi.nlm.nih.gov/35974845
28. Lebas H, Yahiaoui K, Martos R, Boulaftali Y. Platelets Are at the Nexus of Vascular Diseases. Front Cardiovasc Med. 2019;6:132. Available from: https://pubmed.ncbi.nlm.nih.gov/31572732
29. Wang Y, Huang X-M, Zhang Y, Li J, Li J, Ye Z, et al. Comparison of ultrasound features and lesion sites in dysfunctional arteriovenous fistula. Ren Fail. 2024/01/08. 2024;46(1):2294148. Available from: https://pubmed.ncbi.nlm.nih.gov/38186351
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Siti Ayu Meisa Utari, Internship Doctor of Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
Internship Doctor of Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
Ivan Joalsen Mangara Tua, Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
David H Christian, Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
Michael Caesario, Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan
Thoracic Cardiac and Vascular Division, Abdoel Wahab Sjahranie Hospital, Samarinda, East Kalimantan